Several other equities analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Insys Therapeutics from a strong-buy rating to a hold rating in a report on Wednesday, August 9th. Royal Bank Of Canada decreased their price objective on shares of Insys Therapeutics from $16.00 to $14.00 and set an outperform rating on the stock in a report on Friday, August 4th. Piper Jaffray Companies set a $10.00 price objective on shares of Insys Therapeutics and gave the company a hold rating in a report on Wednesday, July 26th. Finally, BidaskClub raised shares of Insys Therapeutics from a strong sell rating to a sell rating in a research report on Saturday, August 26th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of Hold and a consensus price target of $9.38.
Shares of Insys Therapeutics (INSY) traded down $0.05 on Friday, reaching $5.16. 485,500 shares of the company were exchanged, compared to its average volume of 777,138. Insys Therapeutics has a fifty-two week low of $4.10 and a fifty-two week high of $15.02.
WARNING: This piece of content was reported by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://weekherald.com/2017/11/13/insys-therapeutics-inc-insy-given-hold-rating-at-oppenheimer-holdings-inc.html.
Several institutional investors have recently added to or reduced their stakes in INSY. Dynamic Technology Lab Private Ltd acquired a new position in shares of Insys Therapeutics in the third quarter valued at approximately $119,000. SG Americas Securities LLC acquired a new stake in Insys Therapeutics during the 2nd quarter valued at approximately $138,000. Voya Investment Management LLC acquired a new stake in Insys Therapeutics during the 2nd quarter valued at approximately $149,000. American International Group Inc. boosted its holdings in shares of Insys Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 14,462 shares of the specialty pharmaceutical company’s stock worth $152,000 after buying an additional 953 shares in the last quarter. Finally, BNP Paribas Arbitrage SA boosted its holdings in shares of Insys Therapeutics by 213.2% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 13,133 shares of the specialty pharmaceutical company’s stock worth $166,000 after buying an additional 8,940 shares in the last quarter. 25.23% of the stock is owned by institutional investors.
About Insys Therapeutics
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.